EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation Authors: Barbara Eichhorst, Paolo Ghia, Francesc Bosch, Ruth Clifford, Michael Gregor, Romain Guieze, Arnon P. Kater, Carsten U. Niemann, Sarka Pospisilova, Tadeusz Robak, Anna Schuh, Kostas Stamatopoulos, Tamar Tadmor, Nick York Published: 2026 ABSTRACT AbstractPrevious editions of the European guidelines for the management of chronic lymphocytic leukemia (CLL) were developed by experts in CLL under the auspices of the European Society for Medical Oncology (ESMO). These previous editions have served as a reference text for many physicians caring for patients with CLL. The current, 2026 edition, represents the new, updated guidelines that, for the first time (and in agreement with ESMO), were written on behalf of the European Hematology Association (EHA), which will be solely responsible for subsequent editions, published annually to keep pace of the fast‐moving field of CLL research and clinical applications. The new guidelines support approaching the management of CLL in a more holistic fashion, from the initial diagnosis (including active surveillance) to treatment need, with particular emphasis on the interplay between disease‐ and patient‐specific criteria for decision‐making, to the latest stage of possible Richter transformation, which is now specifically mentioned in the title of the guidelines. These new recommendations are the result of a consensus reached among medical experts from several European countries and, for the first time, have involved patient advocacy representatives, which is in line with EHA standard operating procedures for clinical practice guideline development. Updates in terms of treatment options include the recently European Medicines Agency‐approved, time‐limited combination therapy acalabrutinib and venetoclax ± obinutuzumab as first‐line treatment, and continuous pirtobrutinib for patients exposed to covalent Bruton's tyrosine kinase inhibitors in the relapsed/refractory setting. INTRODUCTION AND METHODOLOGY The following clinical practice guidelines for diagnosis, treatment, and follow‐up in patients with chronic lymphocytic leukemia (CLL) and Richter transformation (RT) were, for the first time, written solely under the auspices of the European Hematology Association (EHA), following the spirit and aims of previous versions coordinated by the European Society for Medical Oncology (ESMO). Starting with this update, EHA has taken the responsibility, in agreement with ESMO, to gather representative hematologists from most European countries and with relevant expertise in the management and treatment of patients with CLL, but including now also experts in molecular diagnosis and prognostic stratification. More emphasis is now given to the overall management of patients, from the moment of the initial diagnosis through the active surveillance period, to the time when they need therapy, including the ensuing burden of subsequent relapses and lines of therapies up to rare, but possible, RT. To this aim, patient advocacy representatives are now also involved, bringing the unique perspective of the people who actually are carrying the burden and distress of the disease. Updates are now planned annually, given the fast pace of the developments in the field, which is marked by a continuous flurry of novel diagnostic/prognostic procedures, as well as new drug approvals. For this specific edition, the update follows the approval of the time‐limited combination therapy acalabrutinib + venetoclax ± obinutuzumab as first‐line treatment, and of continuous pirtobrutinib for patients exposed to covalent Bruton's tyrosine kinase (BTK) inhibitors in the relapsed/refractory (R/R) setting. Recommendations are based on available scientific data and the authors' collective expert opinion through a consensus reached using the methodology as described by EHA standard operating procedures for clinical practice guideline development. 1 The relevant literature, including conference proceedings, where relevant, was selected by the expert authors. The European Medicines Agency (EMA) approval status at the time of completion of these guidelines was added, where relevant. We use Level of Evidence and Grade of Recommendation as described in Tables 1A and 1B for evidence‐based recommendations. 2 We are also providing for the first time the Magnitude of Clinical Benefit Scores for Hematologic Malignancies (MCBS:H), which indicates with a score of 4 or 5 a substantial benefit in the noncurative setting. 3 , 4 Table 1ALevel of evidence.IEvidence from at least one large randomized controlled trial (RCT) of good methodological quality (low potential for bias) or meta‐analyses of well‐conducted randomized trials without heterogeneityIISmall randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta‐analyses of such trials or of trials with demonstrated heterogeneityIIIProspective cohort studiesIVRetrospective cohort studies or case‐control studiesVStudies without control group, case reports, expert opinionsJohn Wiley & Sons, Ltd. Level of evidence. Table 1BGrade of recommendation.AStrong evidence for efficacy with a substantial clinical benefit, strongly recommendedBStrong or moderate evidence for efficacy but with a limited clinical benefit, generally recommendedCInsufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, etc.), optionalDModerate evidence against efficacy or for adverse outcome, generally not recommendedEStrong evidence against efficacy or for adverse outcome, never recommendedJohn Wiley & Sons, Ltd. Grade of recommendation. INCIDENCE AND EPIDEMIOLOGY CLL and small lymphocytic lymphoma (SLL) are considered a single entity by the World Health Organization (WHO) 2022 classification (Table 2). 5 The incidence rate of CLL in Europe is 4.7 per 100,000 according to WHO. 6 The median age at diagnosis is 70 years and men are affected nearly twice as much as women. In Western countries, the death rate has decreased from 2.0 per 100,000 decades ago to 1.0 per 100,000 as reported for the 2018–2022 time period. 7 Table 2Definition of CLL, SLL, and MBL.Disease entitySubtypeClonal B lymphocytes in peripheral bloodLymph nodes or splenomegaly or hepatomegalyChronic lymphocytic leukemia (CLL)–≥5 × 109/LNo/Yes (possible for Binet Stage A)Small lymphocytic lymphoma (SLL)–<5 × 109/LYesMonoclonal B‐cell lymphocytosis (MBL)CLL/SLL‐type MBL (previously high‐count MBL)≥0.5 × 109/L, but <5 × 109/LNoLow‐count MBL/clonal B‐cell expansion<0.5 × 109/LNoJohn Wiley & Sons, Ltd. Definition of CLL, SLL, and MBL. DIAGNOSIS, PATHOLOGY, AND MOLECULAR BIOLOGY Diagnosis A diagnosis of CLL is established by immunophenotyping using flow cytometry to document the presence of ≥5 × 109/L clonal B lymphocytes that are positive for CD19, CD5, and CD23. 5 , 8 , 9 CLL cells typically express low levels of CD20, CD79B, and surface immunoglobulin, with either κ or λ immunoglobulin light‐chain restriction or (apparent) absence at flow analysis. 5 , 8 Additional phenotyping (CD43, CD200, ROR1) may assist in differential diagnosis from other clonal B‐lymphoproliferations. 10 SLL, which accounts for about 5% of cases, lacks significant leukemic manifestation (<5 × 109/L clonal B cells) and presents with involvement of secondary lymphoid tissues (Table 2). Monoclonal B‐cell lymphocytosis (MBL) is characterized by the presence of circulating monoclonal B cells with a CLL phenotype, yet at a concentration lower than required for the clinical diagnosis of CLL, without cytopenias, pathological enlargement of secondary lymphoid tissues, or B symptoms. MBL, found in otherwise healthy individuals, is classified into two subtypes based on the number of circulating, CLL‐like B cells 5 , 8 : CLL/SLL‐type MBL (<5 × 109/L and ≥0.5 × 109/L) and low‐count CLL‐type MBL (<0.5 × 109/L) (Table 2). CLL/SLL‐type MBL may evolve into CLL requiring therapy at a rate of 1% per year, 11 whereas low count MBL is not practically associated with overt CLL, albeit persists with time. 12 , 13 Biomarker‐guided stratification in patients with CLL The clinical course of CLL can be very heterogeneous, reflecting its underlying biological heterogeneity. 14 , 15 , 16 , 17 This highlights the need for biomarkers capable of predicting outcomes, particularly the response to a given treatment. Many biomarkers have been identified and found to carry an independent prognostic value. However, patient stratification in clinical practice is in particular based on the somatic hypermutation (SHM) status of clonotypic‐rearranged immunoglobulin heavy variable (IGHV) genes and TP53 aberrations. IGHV gene SHM status The SHM status of the IGHV genes dichotomizes CLL into two major categories with different biology and natural history. 14 , 15 Patients bearing IGHV genes with minimal or no SHM (those differing from the germline by 2% maximum or with ≥98% identity) are classified as IGHV‐unmutated (U‐CLL); these patients often carry adverse prognostic genetic features and typically experience more rapidly progressive disease. In contrast, patients bearing IGHV genes with a significant SHM burden (<98% identity to the germline) are classified as IGHV‐mutated CLL (M‐CLL) and generally experience indolent disease. 14 , 15 The SHM status of the IGHV genes robustly predicts time to first treatment and, more importantly, discriminates patients with different durations of response to different treatments. 18 , 19 Moreover, SHM status remains stable over time, in contrast to other biomarkers (i.e., genomic aberrations by FISH or cytogenetics or TP53 mutations), which may change with disease evolution. 20 However, not all U‐CLL or M‐CLL cases are equivalent, 21 as exemplified by stereotyped subsets (i.e., subgroups of cases expressing [quasi]identical B‐cell receptor immunoglobulin). 18 The most clinically relevant subsets are #2 22 , 23 and #8 24 , 25 both of which are associated with aggressive disease. However, most evidence regarding the clinical and predictive significance of subsets derives from retrospective studies and is still inconclusive, particularly concerning response to targeted therapy. 26 Determination of the SHM status of IGHV genes is performed by DNA/cDNA sequencing using either Sanger or next‐generation sequencing (NGS) 19 ; by default, sequencing also provides information regarding subset membership if performed according to European Research Initiative on CLL (ERIC) recommendations (i.e., sequencing covers the entire variable heavy complementarity‐determining region 3 [VH CDR3] region). NGS offers unprecedented depth of analysis, but comes with challenges, including, among others, the relevance of the 98% germline identity cut‐off value, the importance of intraclonal diversification, and the significance, if any, of minor clonotypes co‐existing with the major one (especially when their SHM status differs). Recommendation Determine SHM status of IGHV genes following ERIC recommendations 19 in all patients with CLL before first‐line treatment Relevant for:All patients in need of first‐line therapyTimepoint:Before first‐line treatmentLevel of EvidenceIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation Determine SHM status of IGHV genes following ERIC recommendations 19 in all patients with CLL before first‐line treatment Relevant for:All patients in need of first‐line therapyTimepoint:Before first‐line treatmentLevel of EvidenceIIGrade of RecommendationBJohn Wiley & Sons, Ltd. TP53 gene aberrations A TP53 aberration is defined as either the deletion of the TP53 gene locus on 17p13 [del(17p)] or the presence of a mutation (i.e., a somatic change in the sequence of the TP53 gene [TP53mut]). The independent negative impact of TP53 aberrations on overall survival (OS) and chemoimmunotherapy (CIT) response has been well documented, and assessing both types of aberrations has become a part of the diagnostic/prognostic assessment. 27 The frequency of TP53 aberrations is low at diagnosis (5%–10% of patients), higher in patients entering first‐line treatment (10%–20%), and increases further at later disease stages, predominantly in patients treated with CIT, and RT (up to 50%). 28 , 29 , 30 , 31 The deletion of the 17p13 locus typically co‐occurs with mutations of the second TP53 allele. They may also be present independently, with a sole del(17p) being less frequent than a sole TP53 mutation, which might be also associated with inactivation of the second allele via copy‐neutral loss of heterozygosity. TP53 aberrations are often subclonal, and the concurrent presence of several distinct TP53‐aberrant subclones is not exceptional. 32 The presence of TP53 aberrations associates with a shorter time to first treatment, at least in patients with U‐CLL. 21 , 33 In CIT‐treated patients, TP53 aberrations shorten OS regardless of number of affected alleles and clone size. 27 , 34 , 35 Further information on the impact of TP53 aberrations for targeted treatment of CLL is included in Section 6 of this publication. Based on the current evidence, both del(17p) and TP53 gene mutations should be assessed before each line of treatment. Fluorescent in‐situ hybridization (FISH) is recommended for detecting del(17p), while NGS is the preferred method for detecting TP53 mutations. In contrast to Sanger sequencing, NGS is capable of detecting TP53 mutations present in small subpopulations that possess a selective advantage under pressure of DNA‐damaging therapy, and that could undergo a clonal expansion. 36 The variant allele frequency (VAF) threshold for determining clinical significance in patients undergoing targeted therapy remains undefined, and reliance on previously established, arbitrary Sanger‐like cut‐offs is no longer scientifically justifiable. 37 Moreover, low‐VAF mutations may represent a major clone in a sample with low cancer‐cell fraction. Because targeted agents act independently of the p53 pathway, they are assumed not to directly accelerate the expansion of TP53‐deficient clones. 29 , 38 Issues therefore remain, such as the impact of allele constitution, oligoclonality, and the clone size in different targeted treatment regimens. Recommendation Determine TP53 aberrations [del(17p) and TP53 gene mutations] by FISH and NGS following ERIC recommendations 37 in all patients with CLL before each treatment line Relevant for:All patients in need of therapy at any lineTimepoint:Before treatment at any lineLevel of EvidenceIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation Determine TP53 aberrations [del(17p) and TP53 gene mutations] by FISH and NGS following ERIC recommendations 37 in all patients with CLL before each treatment line Relevant for:All patients in need of therapy at any lineTimepoint:Before treatment at any lineLevel of EvidenceIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Other genomic aberrations Aberrations in genes other than TP53 (e.g., SF3B1, NOTCH1, POT1, XPO1, NFKBIE, etc.) have been associated with clinical outcomes in patients with CLL, 39 , 40 , 41 with a possible differential impact in M‐CLL versus U‐CLL. 21 However, existing evidence derives from either unplanned post‐hoc analyses of clinical trial cases or from retrospective series, thus precluding firm conclusions from being drawn. On these grounds, testing for such aberrations is not recommended in routine clinical practice, and should be reserved for research purposes only. In recent years, there has been a revival of interest in cytogenetics in CLL, particularly regarding complex karyotype (CK). 42 , 43 In CLL, CK is defined as the presence of ≥3 clonal, structural, or numerical abnormalities, with mounting evidence from (mostly) retrospective studies suggesting that ≥5 aberrations (“high‐CK”) confers the worst prognosis. 43 CK is associated with advanced‐stage disease, U‐CLL, and, particularly, TP53 aberrations. High‐CK has emerged as an independent prognostic factor for inferior progression‐free survival (PFS) in patients with wild‐type TP53 treated with venetoclax‐based combinations. 44 However, the available evidence is still not robust enough to allow for recommendation. 45 The use of CK outside of the research setting is further precluded by technical limitations and limited reproducibility between testing for CK by single‐nucleotide polymorphism array‐based methods and stimulated cytogenetics. Because CLL is familial, but not hereditary, genomic testing for family members is not indicated. Recommendation Due to limited reproducibility, assessment of CK is not recommended before treatment initiation outside clinical trials Relevant for:All patients in need of therapy at any lineTimepoint:Before treatment at any lineLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation Due to limited reproducibility, assessment of CK is not recommended before treatment initiation outside clinical trials Relevant for:All patients in need of therapy at any lineTimepoint:Before treatment at any lineLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. STAGING AND PROGNOSTIC SCORES There are two clinical staging systems for CLL, both carrying prognostic value when applied at the time of diagnosis. These were the first prognostic scores to be described in CLL. The modified Rai classification defines five different stages and three prognostic subgroups 46 , 47 The Binet staging system, more frequently used in Europe, distinguishes three subgroups 48 The modified Rai classification defines five different stages and three prognostic subgroups 46 , 47 The modified Rai classification defines five different stages and three prognostic subgroups 46 , 47 The Binet staging system, more frequently used in Europe, distinguishes three subgroups 48 The Binet staging system, more frequently used in Europe, distinguishes three subgroups 48 Both staging systems use physical examination and full blood count for risk‐group classification, and neither requires nor considers radiological imaging (Table 3). 49 Table 3Binet and Rai classification system.Binet stageRai stageRisk categoryLymphocytosisLymphadenopathya Splenomegaly Hepatomegalya Hemoglobin (g/L)b Platelets (G/L)b Binet ARai 0Low riskPresentNone to <3 absent (Rai) None to <3 Absent (Rai)≥110/100 for Rai/Binet≥100Binet BRai IIntermediate riskPresent≥3 Present (Rai)≥3 Absent (Rai)≥110/100 for Rai/Binet≥100Rai IIPresent≥3 Irrelevant (Rai)≥3 Mandatory (Rai)≥110/100 for Rai/Binet≥100Binet CRai IIIHigh riskPresentIrrelevantIrrelevant<110/100 for Rai/Binet≥100Rai IVPresentIrrelevantIrrelevantIrrelevant<100 Note: SLL is staged using the Lugano classification system. a Enlarged lymph nodes ≥1 cm in diameter or organomegaly by palpation. b Due to bone marrow infiltration (after i.e., excluding autoimmune cytopenia).John Wiley & Sons, Ltd. Binet and Rai classification system. Note: SLL is staged using the Lugano classification system. Enlarged lymph nodes ≥1 cm in diameter or organomegaly by palpation. Due to bone marrow infiltration (after i.e., excluding autoimmune cytopenia). Patients with asymptomatic early‐stage disease (Binet A or Binet B) do not need any further risk assessment, such as biological profiling of CLL. Several clinical trials were not able to show any benefit in terms of OS following treatment, even with targeted drugs, in asymptomatic early‐stage patients in the presence of high‐risk disease characteristics. 50 , 51 , 52 , 53 Classification as high‐risk disease (i.e., neither by International Prognostic nor Index for Chronic Lymphocytic Leukemia 54 or International Prognostic Score for Asymptomatic Early‐Stage CLL 55 ) is not an indication to start treatment for CLL in asymptomatic patients without active disease, as defined by International Workshop on CLL (iwCLL) guidelines. Although SLL is staged using the Lugano classification system, as other types of lymphoma, 49 risk assessment and treatment indication for SLL correspond to those for CLL. NEED FOR TREATMENT Active disease requiring therapy is defined by the IWCLL guidelines. 9 In patients with symptomatic or “active” and advanced CLL (with cytopenias—Binet C or Rai III/IV—or large lymphadenopathies), additional tests are recommended before treatment to assess patient's conditions and disease characteristics that may influence choice of therapy. Pretreatment evaluation includes history and physical examination, laboratory tests, and imaging (Table 4). Additional to the iwCLL 2018 guidelines, radiographic imaging with computed tomography (CT) or magnetic resonance imaging (MRI) scan of neck, chest, abdomen, and pelvis is recommended to assess the tumor load and risk of tumor lysis syndrome whenever treatment with the BCL‐2 (B‐cell lymphoma‐2) inhibitor venetoclax is considered. Table 4Pretherapy testing.History: 1.Focus on symptomatic CLL: B symptoms (weight loss, fevers, night sweats, and fatigue), infections2.History of infections (frequency, severity) and vaccinations3.Focus on relevant comorbidities: cardiovascular, hepatic, or renal disease4.Co‐medications with impact on CLL treatment: anticoagulation, antiplatelet therapy, and potential interactions Physical examinations: 1.ECOG performance status2.Size of lymph nodes, splenomegaly, hepatomegaly3.Complete examination of heart, lungs, abdomen, and skin Laboratory tests: 1.Complete blood count and differential2.Direct antiglobulin test3.Serum chemistry: renal function, hepatic function, lactate dehydrogenase, uric acid, beta‐2‐microglobulin, immunoglobulin IgA, IgG, IgM4.Serology for hepatitis B virus, hepatitis C virus, HIV5.Consider bone marrow biopsy in case of severe/unclear cytopenia for evaluation of percentage of CLL infiltration vs. autoimmune cytopenia Genetic testing: (of peripheral blood lymphocytes) 1.FISH (or array comparative genomic hybridization for del(17p)2. TP53 gene mutations (by sequencing, NGS preferred), reported according to ERIC recommendation3.Molecular analysis for IGHV gene mutation status reported according to ERIC recommendationsa Cardiac testing: 1.Electrocardiogram, cardiac history, and cardiovascular risk assessment in all patients whenever treatment with a BTK inhibitor is considered2.If previous cardiac history or ongoing uncontrolled cardiac comorbidities refer to a cardiologist Radiological imaging: 1.Only required in specific clinical circumstances, for example, CT scans of neck, chest, abdomen and pelvis for evaluation of risk for tumor lysis syndrome only in patients for whom the BCL‐2 inhibitor venetoclax is considered. a IGHV gene mutation status remains stable during the disease course, hence needs to be determined only once, usually before first‐line therapy. Genetic testing for deletion of chromosome 17 by FISH and sequencing for detection of TP53 mutations as well as all other tests are required before first and any subsequent lines of treatment.John Wiley & Sons, Ltd. Pretherapy testing. 1.Focus on symptomatic CLL: B symptoms (weight loss, fevers, night sweats, and fatigue), infections2.History of infections (frequency, severity) and vaccinations3.Focus on relevant comorbidities: cardiovascular, hepatic, or renal disease4.Co‐medications with impact on CLL treatment: anticoagulation, antiplatelet therapy, and potential interactions 1.Focus on symptomatic CLL: B symptoms (weight loss, fevers, night sweats, and fatigue), infections Focus on symptomatic CLL: B symptoms (weight loss, fevers, night sweats, and fatigue), infections 2.History of infections (frequency, severity) and vaccinations History of infections (frequency, severity) and vaccinations 3.Focus on relevant comorbidities: cardiovascular, hepatic, or renal disease Focus on relevant comorbidities: cardiovascular, hepatic, or renal disease 4.Co‐medications with impact on CLL treatment: anticoagulation, antiplatelet therapy, and potential interactions Co‐medications with impact on CLL treatment: anticoagulation, antiplatelet therapy, and potential interactions 1.ECOG performance status2.Size of lymph nodes, splenomegaly, hepatomegaly3.Complete examination of heart, lungs, abdomen, and skin 1.ECOG performance status ECOG performance status 2.Size of lymph nodes, splenomegaly, hepatomegaly Size of lymph nodes, splenomegaly, hepatomegaly 3.Complete examination of heart, lungs, abdomen, and skin Complete examination of heart, lungs, abdomen, and skin 1.Complete blood count and differential2.Direct antiglobulin test3.Serum chemistry: renal function, hepatic function, lactate dehydrogenase, uric acid, beta‐2‐microglobulin, immunoglobulin IgA, IgG, IgM4.Serology for hepatitis B virus, hepatitis C virus, HIV5.Consider bone marrow biopsy in case of severe/unclear cytopenia for evaluation of percentage of CLL infiltration vs. autoimmune cytopenia 1.Complete blood count and differential Complete blood count and differential 2.Direct antiglobulin test Direct antiglobulin test 3.Serum chemistry: renal function, hepatic function, lactate dehydrogenase, uric acid, beta‐2‐microglobulin, immunoglobulin IgA, IgG, IgM Serum chemistry: renal function, hepatic function, lactate dehydrogenase, uric acid, beta‐2‐microglobulin, immunoglobulin IgA, IgG, IgM 4.Serology for hepatitis B virus, hepatitis C virus, HIV Serology for hepatitis B virus, hepatitis C virus, HIV 5.Consider bone marrow biopsy in case of severe/unclear cytopenia for evaluation of percentage of CLL infiltration vs. autoimmune cytopenia Consider bone marrow biopsy in case of severe/unclear cytopenia for evaluation of percentage of CLL infiltration vs. autoimmune cytopenia 1.FISH (or array comparative genomic hybridization for del(17p)2. TP53 gene mutations (by sequencing, NGS preferred), reported according to ERIC recommendation3.Molecular analysis for IGHV gene mutation status reported according to ERIC recommendationsa 1.FISH (or array comparative genomic hybridization for del(17p) FISH (or array comparative genomic hybridization for del(17p) 2. TP53 gene mutations (by sequencing, NGS preferred), reported according to ERIC recommendation TP53 gene mutations (by sequencing, NGS preferred), reported according to ERIC recommendation 3.Molecular analysis for IGHV gene mutation status reported according to ERIC recommendationsa Molecular analysis for IGHV gene mutation status reported according to ERIC recommendationsa 1.Electrocardiogram, cardiac history, and cardiovascular risk assessment in all patients whenever treatment with a BTK inhibitor is considered2.If previous cardiac history or ongoing uncontrolled cardiac comorbidities refer to a cardiologist 1.Electrocardiogram, cardiac history, and cardiovascular risk assessment in all patients whenever treatment with a BTK inhibitor is considered Electrocardiogram, cardiac history, and cardiovascular risk assessment in all patients whenever treatment with a BTK inhibitor is considered 2.If previous cardiac history or ongoing uncontrolled cardiac comorbidities refer to a cardiologist If previous cardiac history or ongoing uncontrolled cardiac comorbidities refer to a cardiologist 1.Only required in specific clinical circumstances, for example, CT scans of neck, chest, abdomen and pelvis for evaluation of risk for tumor lysis syndrome only in patients for whom the BCL‐2 inhibitor venetoclax is considered. 1.Only required in specific clinical circumstances, for example, CT scans of neck, chest, abdomen and pelvis for evaluation of risk for tumor lysis syndrome only in patients for whom the BCL‐2 inhibitor venetoclax is considered. Only required in specific clinical circumstances, for example, CT scans of neck, chest, abdomen and pelvis for evaluation of risk for tumor lysis syndrome only in patients for whom the BCL‐2 inhibitor venetoclax is considered. IGHV gene mutation status remains stable during the disease course, hence needs to be determined only once, usually before first‐line therapy. Genetic testing for deletion of chromosome 17 by FISH and sequencing for detection of TP53 mutations as well as all other tests are required before first and any subsequent lines of treatment. According to iwCLL 2018 at least 1 of the following criteria should be met: 1.Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia. Cut‐off levels of hemoglobin <100 g/L or platelet counts <100 G/L are generally regarded as indication for treatment. However, in some patients, platelet counts <100 G/L may remain stable over a long period; this situation does not automatically require therapeutic intervention.2.Massive lymph nodes (i.e., >10 cm in longest diameter) or progressive or symptomatic lymphadenopathy.3.Massive (i.e., >6 cm below the left costal margin) or progressive or symptomatic splenomegaly.4.Progressive lymphocytosis with an increase of >50% over a 2‐month period, or lymphocyte doubling time (LDT) < 6 months. LDT can be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of 2 weeks over an observation period of 2 to 3 months; patients with initial blood lymphocyte counts >30 G/L may require a longer observation period to determine the LDT. Factors contributing to lymphocytosis other than CLL (e.g., infections, steroid administration) should be excluded.5.Autoimmune complications including anemia or thrombocytopenia poorly responsive to corticosteroids.6.Symptomatic or functional extranodal involvement (e.g., skin, kidney, lung, spine).7.Disease‐related symptoms as defined by any of the following: a.Unintentional weight loss of >10% within the previous 6 months.b.Significant fatigue (i.e., Eastern Cooperative Oncology Group [ECOG] performance status of 2 or worse; cannot work or unable to perform usual activities).c.Fevers >100.5°F or 38.0°C for 2 or more weeks without evidence of infection.d.Night sweats for >1 month without evidence of infection. 1.Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia. Cut‐off levels of hemoglobin <100 g/L or platelet counts <100 G/L are generally regarded as indication for treatment. However, in some patients, platelet counts <100 G/L may remain stable over a long period; this situation does not automatically require therapeutic intervention. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia. Cut‐off levels of hemoglobin <100 g/L or platelet counts <100 G/L are generally regarded as indication for treatment. However, in some patients, platelet counts <100 G/L may remain stable over a long period; this situation does not automatically require therapeutic intervention. 2.Massive lymph nodes (i.e., >10 cm in longest diameter) or progressive or symptomatic lymphadenopathy. Massive lymph nodes (i.e., >10 cm in longest diameter) or progressive or symptomatic lymphadenopathy. 3.Massive (i.e., >6 cm below the left costal margin) or progressive or symptomatic splenomegaly. Massive (i.e., >6 cm below the left costal margin) or progressive or symptomatic splenomegaly. 4.Progressive lymphocytosis with an increase of >50% over a 2‐month period, or lymphocyte doubling time (LDT) < 6 months. LDT can be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of 2 weeks over an observation period of 2 to 3 months; patients with initial blood lymphocyte counts >30 G/L may require a longer observation period to determine the LDT. Factors contributing to lymphocytosis other than CLL (e.g., infections, steroid administration) should be excluded. Progressive lymphocytosis with an increase of >50% over a 2‐month period, or lymphocyte doubling time (LDT) < 6 months. LDT can be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of 2 weeks over an observation period of 2 to 3 months; patients with initial blood lymphocyte counts >30 G/L may require a longer observation period to determine the LDT. Factors contributing to lymphocytosis other than CLL (e.g., infections, steroid administration) should be excluded. 5.Autoimmune complications including anemia or thrombocytopenia poorly responsive to corticosteroids. Autoimmune complications including anemia or thrombocytopenia poorly responsive to corticosteroids. 6.Symptomatic or functional extranodal involvement (e.g., skin, kidney, lung, spine). Symptomatic or functional extranodal involvement (e.g., skin, kidney, lung, spine). 7.Disease‐related symptoms as defined by any of the following: a.Unintentional weight loss of >10% within the previous 6 months.b.Significant fatigue (i.e., Eastern Cooperative Oncology Group [ECOG] performance status of 2 or worse; cannot work or unable to perform usual activities).c.Fevers >100.5°F or 38.0°C for 2 or more weeks without evidence of infection.d.Night sweats for >1 month without evidence of infection. Disease‐related symptoms as defined by any of the following: a.Unintentional weight loss of >10% within the previous 6 months.b.Significant fatigue (i.e., Eastern Cooperative Oncology Group [ECOG] performance status of 2 or worse; cannot work or unable to perform usual activities).c.Fevers >100.5°F or 38.0°C for 2 or more weeks without evidence of infection.d.Night sweats for >1 month without evidence of infection. a.Unintentional weight loss of >10% within the previous 6 months. Unintentional weight loss of >10% within the previous 6 months. b.Significant fatigue (i.e., Eastern Cooperative Oncology Group [ECOG] performance status of 2 or worse; cannot work or unable to perform usual activities). Significant fatigue (i.e., Eastern Cooperative Oncology Group [ECOG] performance status of 2 or worse; cannot work or unable to perform usual activities). c.Fevers >100.5°F or 38.0°C for 2 or more weeks without evidence of infection. Fevers >100.5°F or 38.0°C for 2 or more weeks without evidence of infection. d.Night sweats for >1 month without evidence of infection. Night sweats for >1 month without evidence of infection. Recommendation Treatment should only be initiated when iwCLL criteria are met Relevant for:All patients with progressionLevel of EvidenceIa Grade of RecommendationA a This has only been properly tested in the treatment‐naive setting; implemented in the R/R CLL setting with very limited evidence.John Wiley & Sons, Ltd. Recommendation Treatment should only be initiated when iwCLL criteria are met Relevant for:All patients with progressionLevel of EvidenceIa Grade of RecommendationA a This has only been properly tested in the treatment‐naive setting; implemented in the R/R CLL setting with very limited evidence.John Wiley & Sons, Ltd. This has only been properly tested in the treatment‐naive setting; implemented in the R/R CLL setting with very limited evidence. COMPREHENSIVE MANAGEMENT DURING ACTIVE SURVEILLANCE: GENERAL APPROACH INCLUDING MANAGEMENT OF AUTOIMMUNE CYTOPENIAS (AIC) Here, we provide a concise description of the minimal requirements for the management of patients following diagnosis of CLL during active surveillance. Infection prophylaxis Vaccinations A hallmark of CLL is progressive immunodeficiency. 56 Vaccination against pneumococcus, varicella zoster, and hepatitis B viruses is advised, despite somewhat impaired response, 57 , 58 , 59 , 60 , 61 while less evidence is present for respiratory syncytial virus. Vaccination against seasonal viruses, such as influenza and SARS‐CoV‐2/COVID19, should be administered and repeated according to the national recommendations. Specifically, the varicella zoster virus (VZV) recombinant vaccine against VZV glycoprotein E (Shingrix®) is safe, and has good immunogenicity and efficacy (even in heavily pre‐treated patients). 62 If a patient has a history of shingles, (val)aciclovir could be considered as secondary prophylaxis in addition to the VZV vaccine. At diagnosis, conjugate pneumococcal vaccine 20‐valent (PCV20) is recommended, followed at least 2 months later by polysaccharide pneumococcal vaccine polyvalent (PPV23). Vaccination should be repeated every 5 years. Patients who have been previously vaccinated with PPV23 only should receive a “catch‐up” dose of PCV20. Live vaccines (measles/mumps/rubella, live polio, yellow fever, and varicella vaccine [Zostavax®]) should not be given. Patients should avoid contact with children who have received the live nasal influenza vaccine or the polio oral vaccine for seven days. Recommendation Vaccination against pneumococcus, varicella zoster, and hepatitis B virusesRelevant for:All patients under surveillance, even with expected impaired response to vaccinationLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation Vaccination against pneumococcus, varicella zoster, and hepatitis B virusesRelevant for:All patients under surveillance, even with expected impaired response to vaccinationLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation Seasonal repetitive vaccination against influenza and SARS‐CoV‐2/COVID19Relevant for:All patients under surveillance, even with expected impaired response to vaccinationLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation Seasonal repetitive vaccination against influenza and SARS‐CoV‐2/COVID19Relevant for:All patients under surveillance, even with expected impaired response to vaccinationLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation No live vaccines should be givenRelevant for:All patientsLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation No live vaccines should be givenRelevant for:All patientsLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Antimicrobial prophylaxis Recommendation Antimicrobial prophylaxis is not generally recommendedRelevant for:All patientsLevel of EvidenceIVGrade of RecommendationDJohn Wiley & Sons, Ltd. Recommendation Antimicrobial prophylaxis is not generally recommendedRelevant for:All patientsLevel of EvidenceIVGrade of RecommendationDJohn Wiley & Sons, Ltd. Immunoglobulin replacement therapy The incidence of recurrent infections combined with hypogammaglobulinemia increases with duration of CLL. Immunoglobulin (Ig) replacement therapy is advised for patients who suffer recurrent or acute infections and have a total IgG <4 g/L. 63 Subcutaneous Ig preparations are associated with higher IgG trough levels, fewer adverse events, and improved patient quality of life compared to intravenous formulations. 64 , 65 , 66 Recommendation Ig replacement is only advised with recurrent symptomatic or active infections needing hospitalization, in addition to laboratory‐confirmed hypogammaglobulinemia Relevant for:All patients with recurrent symptomatic or active infections in addition to laboratory confirmed hypogammaglobulinemiaLevel of EvidenceIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation Ig replacement is only advised with recurrent symptomatic or active infections needing hospitalization, in addition to laboratory‐confirmed hypogammaglobulinemia Relevant for:All patients with recurrent symptomatic or active infections in addition to laboratory confirmed hypogammaglobulinemiaLevel of EvidenceIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Prevention of secondary cancers and lifestyle Patients with CLL have an increased risk for other cancers, even prior to receiving treatment. 67 Family counselling should only be considered in patients with a strong family history of CLL, other cancers, autoimmune disease or immunodeficiency, or a confirmed diagnosis of constitutional cancer syndromes (e.g., Li Fraumeni syndrome). Polygenic single‐nucleotide polymorphisms conferring a higher risk for familial CLL remain an area of active research and should not be screened for. 68 All patients should be informed of the availability of cancer prevention screenings for the general population and should be motivated particularly to join them. They should also be informed of the importance of non‐smoking due to the increased risk of lung cancer and the use of ultraviolet protection due to the skin cancer risk. Need for regular skin assessment by a dermatologist or general practitioner should be considered with all patients, in particular in those considered at risk of skin cancer (e.g., light skin combined with sun exposure). Recommendation All patients should be informed of the availability of cancer prevention screenings and should be motivated particularly to join them Relevant for:All patientsLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation All patients should be informed of the availability of cancer prevention screenings and should be motivated particularly to join them Relevant for:All patientsLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Management of AIC AIC has been reported in 5%–10% of patients during their CLL course, and precedes a diagnosis of CLL in 9% of cases. 69 A bone marrow biopsy may be needed to differentiate between CLL involvement leading to cytopenia and AIC. Many patients present no concomitant indication to treat the underlying CLL, and can be managed with immunosuppression together with supportive measures (as in idiopathic AIC). 70 Autoimmune hemolytic anemia Up to 33% of patients with CLL have a positive direct antiglobulin test at some stage, but overt warm autoimmune hemolytic anemia (wAIHA) occurs less often. 71 For patients with wAIHA and concurrent CLL not meeting iwCLL criteria for treatment, immunosuppression is recommended before considering CLL‐directed therapy. Most interventional studies have focused on studying wAIHA irrespective of the underlying cause. Two small, randomized studies demonstrate superiority of steroids + rituximab versus steroids alone in patients with active wAIHA with regards to response rates and duration. 72 If CLL‐directed therapy is indicated in line with iwCLL criteria, BTK or BCL‐2 inhibitors in combination with an anti‐CD20 antibody may be an option to control wAIHA as well as the underlying CLL. 73 Cold agglutinin disease Cold agglutinin disease should be treated by keeping patients and transfusions warm. Patients needing medical intervention should receive rituximab monotherapy in the first line as steroids cause more adverse events and are less effective. 74 Immune thrombocytopenia (ITP) Approximately 2%–5% patients with CLL develop ITP, mainly when not receiving CLL‐directed treatment 75 , 76 ; about 30% of cases also have a history of AIHA (Evans syndrome). Response to first‐line treatment with steroids or intravenous Ig is 50%–60%. 71 Weekly rituximab for 4 weeks is an effective treatment. 77 The thrombopoietin‐receptor agonist eltrombopag has shown responses in CLL‐associated ITP in a phase 2 study. 78 Splenectomy is an exceptional procedure in selected refractory cases. However, before considering second‐ or third‐line therapy of ITP, treatment of CLL is recommended. Other autoimmune manifestations Pure red cell aplasia and autoimmune neutropenia are rare complications with an incidence of <1%. The treatment approach is the same as for AIHA. 79 Recommendation Patients with an established diagnosis of AIC and requirement of treatment for CLL should receive CLL treatment as recommended for all other CLLPatients without need of treatment for CLL should receive corticosteroid treatment ± Ig(s)In case of unsatisfactory response, the anti‐CD20 antibody rituximab may be used, or CLL treatment should be startedRelevant for:All patients with CLL and AICLevel of EvidenceIVGrade of RecommendationAJohn Wiley & Sons, Ltd. Recommendation Patients with an established diagnosis of AIC and requirement of treatment for CLL should receive CLL treatment as recommended for all other CLLPatients without need of treatment for CLL should receive corticosteroid treatment ± Ig(s)In case of unsatisfactory response, the anti‐CD20 antibody rituximab may be used, or CLL treatment should be startedRelevant for:All patients with CLL and AICLevel of EvidenceIVGrade of RecommendationAJohn Wiley & Sons, Ltd. Psychological implications, support, and lifestyle CLL is a chronically relapsing and remitting leukemia. It is being diagnosed at a younger patient age than in the past due to easier access to blood testing. It is therefore particularly important that patients can establish a long‐term relationship of trust with their physician and other healthcare professionals. A diagnosis of CLL often comes as a total surprise, and can be overwhelming for patients and their families, who may find it difficult to understand, before the complexities of treatments, the concept of active monitoring without an intervention, resulting in “watch, wait, worry,” right at the time of the initial diagnosis when the word “leukemia” bears dramatic scenarios in the public domain. 80 Patients will expect and are entitled to be honestly informed about their disease, and in particular of the peculiarities in comparison to other hematological malignancies where interventions are immediately required. Physicians should be encouraged to differentiate the timing of the follow‐up according to the dynamic and clinical behavior of the disease throughout time. Analysis of other molecular prognostic factors should be limited and encouraged to patients in need of treatment. Patients should be empowered to implement lifestyle measures like good hand hygiene to reduce risk of infections, while informing about the importance of continued social interactions to reduce risk of isolation, emphasizing that contact infection can be largely prevented by hand sanitizers, and that risk of infection in the outdoor setting is very limited. A healthy diet without processed ingredients, aerobic exercise, and managing fatigue by adjustment of daily activities are strongly advised, along with medical interventions such as vaccination and cancer screenings. The role of vitamin D and other supplements in prevention of disease progression remains uncertain. 81 , 82 Recommendation Vitamin D and other supplements do not have to be prescribed routinely for CLL, because their benefit with respect to prevention of progressing disease is uncertain Relevant for:All patientsLevel of EvidenceIIIGrade of RecommendationCJohn Wiley & Sons, Ltd. Recommendation Vitamin D and other supplements do not have to be prescribed routinely for CLL, because their benefit with respect to prevention of progressing disease is uncertain Relevant for:All patientsLevel of EvidenceIIIGrade of RecommendationCJohn Wiley & Sons, Ltd. Support to people living with CLL Regardless of the disease phase, patients with CLL have diverse needs. A patient‐centered approach should take into account different aspects, such as the spectrum of symptoms and clinical manifestations of the disease, the patient's age and overall physical condition (including comorbidities), the treatment aim, the medication plan and its impact on the quality of life, life expectancy, lifestyle and exposures (including concurrent medication), patient preferences, and health literacy, among others. 10 Some of these aspects are dynamic by nature, adding further difficulties in adequately addressing the individual patient's needs. Communication with the healthcare team and the attending physician is very important throughout the disease trajectory, especially when decisions are to be made or transitions are taking place, for example when a new therapy option is discussed or when the goal of care changes. 83 Patient associations are another important vehicle for enhancing CLL‐related literacy. Attending peer‐group meetings and interacting with peers may help patients feel part of a wider community and, thus, develop a sense of belonging. Seeing others who had been diagnosed with CLL years previously and listening to their stories can reduce patients' fears and give hope, making them feel more certain and more in control of their future, as well as more empowered to communicate better with their healthcare team. This reinforces the potential for applying patient‐centered and integrated care, 84 leading to higher compliance during follow‐up and lower levels of stress in daily life. National patient support organizations are a valuable resource for people affected by a diagnosis of CLL (not only patients but also care partners and families). More generally, international non‐profit organizations worldwide can provide access to reliable information, support, and peer connection to aid empowerment. Examples of resources available for use by all relevant stakeholders (including people living with CLL and their care providers, patient advocacy groups, and healthcare professionals) are those offered by: CLL Advocates Network (CLLAN) directory of organizations and resources: https://www.clladvocates.net/.PEOPLE WITH CLL‐ERIC: https://ericll.org/for-patients/people-with-cll/. CLL Advocates Network (CLLAN) directory of organizations and resources: https://www.clladvocates.net/. CLL Advocates Network (CLLAN) directory of organizations and resources: https://www.clladvocates.net/. PEOPLE WITH CLL‐ERIC: https://ericll.org/for-patients/people-with-cll/. PEOPLE WITH CLL‐ERIC: https://ericll.org/for-patients/people-with-cll/. FIRST‐LINE TREATMENT FOR CLL Given the availability of multiple, similarly effective agents for treatment‐naive CLL, treatment selection should be guided by a range of factors beyond drug efficacy alone. Key considerations include TP53 aberrations and IGHV mutational status, patient preference, ECOG performance status, and the presence of comorbid conditions (in particular cardiovascular conditions including hypertension), as well as duration of treatment and method of administration, the treatment toxicity profile, and potential drug–drug interactions (Figure 2). Dose modifications may be required in patients with renal impairment, hepatic dysfunction, or polypharmacy. Drug–drug interactions must be carefully assessed, particularly with venetoclax, which is metabolized via cytochrome P450, family 3, subfamily A (CYP3A), and may interact with azoles, macrolides, or other commonly used medications. Participation within a clinical trial should also be encouraged whenever possible. For greater clarity, the various treatment options have been categorized into time‐limited, continuous, and those for patients with TP53 aberrations. Response assessment should be done according to the iwCLL criteria, which differentiate between clinical practice and clinical trials. In clinical practice specific examinations as CT scans or bone marrow biopsy are not routinely required unless clinically indicated. Time‐limited treatment Time‐limited treatment, typically based on combinations including the BCL‐2 antagonist venetoclax, either in combination with a covalent BTK inhibitor or/and the CD20 antibody obinutuzumab, induces deep responses, limits the emergence of resistant clones, and reduces long‐term toxicity. Two phase III RCTs have outlined the superiority of venetoclax + obinutuzumab to CT regimens (chlorambucil + obinutuzumab, bendamustine + rituximab [BR], and fludarabine + cyclophosphamide + rituximab [FCR]) in terms of PFS and treatment‐free interval (clinical trials CLL14 and CLL13). Long‐term follow‐up data for CLL14 (venetoclax + obinutuzumab vs. chlorambucil, obinutuzumab) in 432 patients with treatment‐naive disease with coexisting comorbidity burden revealed a median PFS of 76.2 months (hazard ratio [HR]: 0.40; P < 0.0001). 86 For venetoclax + obinutuzumab‐treated patients, a shorter PFS was noted in the unmutated IGHV group, and a median PFS not reached for patients with mutated IGHV (HR: 2.66; 95% confidence interval [CI]: 1.63, 4.34). Similar results were obtained within the CLL13 study for patients with low comorbidity burden comparing FCR or BR with venetoclax + rituximab, venetoclax + obinutuzumab, and venetoclax + obinutuzumab + ibrutinib. Five‐year PFS was higher with venetoclax + obinutuzumab + ibrutinib (85.5%) and venetoclax + obinutuzumab (81.8%) versus venetoclax, rituximab (70.1%) and CIT (62.0%). 87 However, infection rates were higher with the triple combination (Grade 3 and 4 infections: 21%). Venetoclax + obinutuzumab was superior to the rituximab combination. Combining venetoclax with covalent BTK inhibitors is another option for time‐limited treatment. With ibrutinib, high efficacy has been observed in three phase 3 RCTs (GLOW, FLAIR, and CLL17) and in the phase 2 CAPTIVATE study. 88 , 89 , 90 , 91 Venetoclax + ibrutinib, given as time‐limited treatment for a total of 15 months within the GLOW study in older (age ≥65 years) or unfit patients, yielded PFS rates of 59.9% after a median of 64 months. 90 The CAPTIVATE study enrolled younger patients (age ≤70 years) to receive venetoclax + ibrutinib, and reported PFS and OS at 5.5 years of 66% and 97%, respectively. 91 Estimated 5.5 PFS year rates were 55% (95% CI: 45, 64) for patients with unmutated IGHV and 79% (95% CI: 68, 87) for patients with mutated IGHV. 91 A non‐fixed duration, but measurable residual disease (MRD)‐driven approach of venetoclax + ibrutinib was assessed in the FLAIR trial. 88 With a median follow‐up of 62.2 months, 5‐year PFS was 93.9% with venetoclax + ibrutinib, 79.0% with ibrutinib alone, and 58.1% with FCR. 88 In a subgroup analysis for the unmutated IGHV group, an OS advantage was seen in the venetoclax + ibrutinib arm over both ibrutinib and FCR. This study, as well as two other phase 2 trials with MRD‐driven design (arm D of SEQUOIA 92 and HO158/NextSTEP trial 93 ) for the combinations venetoclax + zanubrutinib and venetoclax + ibrutinib, highlight excellent outcomes using MRD‐driven guidance for personalized venetoclax + BTK inhibitor duration, but this combination is currently unlicensed. Besides the second‐generation BTK inhibitor zanubrutinib, acalabrutinib has also been evaluated in combination with venetoclax, and was approved in 2025 based on the phase 3 AMPLIFY study comparing acalabrutinib + venetoclax ± obinutuzumab for a total of 14 cycles versus FCR or BR. 94 The estimated 36‐month PFS rates were 76.5% for the doublet, 83.1% for the triplet, and 66.5% for CIT (P = 0.004) with a major difference in particular in CLL with unmutated IGHV status and an OS advantage seen in the venetoclax + acalabrutinib arm, but not for the triplet arm (HR: 0.33, P < 0.0001). 94 The direct comparison between ibrutinib and venetoclax + obinutuzumab and venetoclax + ibrutinib showed no difference in PFS after 3 years of observation in the CLL17 trial. 89 In contrast to the subgroup of patients with TP53 aberrations, in whom there was a trend towards inferior PFS, no major differences were observed between continuous and time‐limited treatment at this time point for patients with mutated and unmutated IGHV status, which may change over time. However—when possible, considering renal function and ramp‐up process—time‐limited treatment should be given preference in the latter subgroups of patients. Decision algorithm for first‐line therapy of patients with CLL. CLL, chronic lymphocytic leukemia; IGHV, immunoglobulin heavy variable. First‐line therapy of patients with CLL: Integrated vision of individual features to guide treatment decision. CLL, chronic lymphocytic leukemia; IGHV, immunoglobulin heavy variable. Figure adapted from Ref. 85. Based on the RCT data outlined above, time‐limited treatment CIT (FCR, BR, chlorambucil + obinutuzumab) is no longer recommended when targeted treatment options are available. Recommendation CITs are no longer recommended, because they are either inferior (BR, chlorambucil + obinutuzumab) to targeted agents or associated with a higher risk for adverse events including secondary neoplasia such as myeloid malignancies (FCR) Relevant for:All patientsLevel of EvidenceIGrade of RecommendationAJohn Wiley & Sons, Ltd. Recommendation CITs are no longer recommended, because they are either inferior (BR, chlorambucil + obinutuzumab) to targeted agents or associated with a higher risk for adverse events including secondary neoplasia such as myeloid malignancies (FCR) Relevant for:All patientsLevel of EvidenceIGrade of RecommendationAJohn Wiley & Sons, Ltd. Recommendation Time‐limited targeted therapies should be preferred over continuous therapy in patients with CLL without TP53 aberrations (Figure 1 ) Relevant for:All patientsLevel of EvidenceIGrade of RecommendationAJohn Wiley & Sons, Ltd. Recommendation Time‐limited targeted therapies should be preferred over continuous therapy in patients with CLL without TP53 aberrations (Figure 1 ) Relevant for:All patientsLevel of EvidenceIGrade of RecommendationAJohn Wiley & Sons, Ltd. Recommendation The selection of combination therapy should take into consideration the biological profile of the CLL and the adverse event profile of the agents, as well as the patient's comorbidities, co‐medications, history of infections, and ease of treatment (Figure 2 ). In particular, in patients with CLL and mutated IGHV status, continuous therapy should be avoided Relevant for:All patientsLevel of EvidenceIIGrade of RecommendationAJohn Wiley & Sons, Ltd. Recommendation The selection of combination therapy should take into consideration the biological profile of the CLL and the adverse event profile of the agents, as well as the patient's comorbidities, co‐medications, history of infections, and ease of treatment (Figure 2 ). In particular, in patients with CLL and mutated IGHV status, continuous therapy should be avoided Relevant for:All patientsLevel of EvidenceIIGrade of RecommendationAJohn Wiley & Sons, Ltd. Continuous treatment Overall, covalent BTK inibition (as either a single agent or in combination with CD20 antibodies) has excellent efficacy in both mutated and unmutated IGHV subgroups, and has demonstrated advantage over CIT in large, randomized trials. Long‐term data from the RESONATE‐2 study comparing ibrutinib with chlorambucil, with up to 10 years of follow‐up, demonstrate that patients treated with ibrutinib experience a sustained PFS benefit versus with chlorambucil (median PFS: 8.9 years). 95 Second‐generation covalent BTK inhibitors, such as acalabrutinib and zanubrutinib, are more selective than ibrutinib, and have demonstrated less off‐target inhibition with fewer toxicities—most notably, fewer cardiac toxicities. 96 , 97 In the phase 3, ELEVATE‐TN study, 535 patients with previously‐untreated CLL were randomized to acalabrutinib + obinutuzumab, acalabrutinib monotherapy, or chlorambucil + obinutuzumab. 98 The estimated 72‐month PFS rates were highest for the combination of acalabrutinib + obinutuzumab (78% vs. 62% for acalabrutinib monotherapy and 17% for CIT), but was associated with more toxicity, in particular cytopenias and infections. 98 Because of the cost‐benefit balance the addition of CD20 antibody should be considered with caution (Figure 1). Continuous treatment with zanubrutinib resulted in a 76% PFS rate after 5 years (median observation time) in the phase 3 SEQUOIA trial of continuous therapy with zanubrutinib versus BR in elderly fit patients. 99 The improved safety profiles of second‐generation BTK inhibitors vs ibrutinib, most notably reduced cardiac toxicity, while directly assessed only in the R/R setting in the ELEVATE R/R 100 and ALPINE 97 clinical trials, has led to a general recommendation of either acalabrutinib or zanubrutinib over ibrutinib in both the first‐line and R/R setting. However, treatment with ibrutinib can be continued if already initiated and well tolerated. Data is emerging to support continuous therapy with second‐generation BTK inhibitors in elderly or frail (e.g., less resilient) patients who may not be candidates for time‐limited treatment. 101 Acalabrutinib + obinutuzumab is more effective than acalabrutinib alone but with additional toxicity, and should not be preferred over acalabrutinib alone (Figure 1). 98 The noncovalent BTK inhibitor (ncBTKi) pirtobrutinib was successfully evaluated in phase III frontline triaals against BR and ibrutinib though it is not yet approved, in this setting. 102 , 103 In addition, the lack of data on subsequent successful use of cBTKi following ncBTKi is currently preventing recommendations to use this compound in frontline. It is recommended to perform a thorough cardiovascular work‐up before initiating BTK inhibitor therapy in order to identify conditions amenable to pre‐emptive intervention, including optimization of antihypertensive therapy. BTK inhibitor therapy should generally be avoided in those with a history of ventricular arrhythmias or uncontrolled heart failure. If there is coexisting cardiovascular disease or the need for anticoagulant treatment, the use of BCL‐2 inhibitors is favored over BTK inhibitors (Figure 2). Recommendation Acalabrutinib and zanubrutinib should be preferred over ibrutinib for continuous treatment of all new patients on the basis of their favorable toxicity profiles Patients who are well controlled on ibrutinib without notable adverse events should not be switched to second‐generation BTK inhibitors Relevant for:All patientsLevel of EvidenceIGrade of RecommendationAJohn Wiley & Sons, Ltd. Recommendation Acalabrutinib and zanubrutinib should be preferred over ibrutinib for continuous treatment of all new patients on the basis of their favorable toxicity profiles Patients who are well controlled on ibrutinib without notable adverse events should not be switched to second‐generation BTK inhibitors Relevant for:All patientsLevel of EvidenceIGrade of RecommendationAJohn Wiley & Sons, Ltd. TP53 disruption Targeted therapies have improved outcomes for patients with TP53 disruption. BTK inhibitors show activity in patients with TP53 disruption. A phase 2 trial, PCYC‐1102, showed a median PFS of 53 months with ibrutinib as a single agent in 34 patients with treatment‐naïve CLL and TP53 alterations. 104 Second‐generation BTK inhibitors are also effective in this patient cohort, reflected in high PFS rates in both the ELEVATE‐TN 98 and SEQUOIA arm C studies, 105 and should be preferred over ibrutinib for safety reasons, as depicted above. The approved venetoclax + ibrutinib combination was evaluated in the phase 2 CAPTIVATE study, which showed 5.5‐year PFS of 30% overall and 47% in those who achieved undetectable MRD. 91 Zanubrutinib + venetoclax, given for 24 cycles (with extension in the majority patients due to persistence of detectable MRD) showed a promising PFS rate of 88% after 3 years in 66 patients with TP53 aberrant disease in the arm D SEQUOIA study, 92 but this combination is not yet licensed. Venetoclax + obinutuzumab showed a shorter PFS in the subgroup analysis of CLL17 (HR for venetoclax + obinutuzumab vs ibrutinib: 1.20, 95% CI: 0.40, 3.59; HR for venetoclax + ibrutinib vs. ibrutinib: 0.70, 95% CI: 0.22, 2.16). 89 Triple combinations with acalabrutinib + venetoclax + obinutuzumab or ibrutinib + venetoclax + obinutuzumab show remarkable results in phase 2 trials for these very high‐risk patients (70% at 4 years and 80% PFS at 3 years, respectively), 106 , 107 but data from randomized trials comparing doublet versus triplet therapy are still pending. These data indicate that triple combinations may be considered for patients with TP53 disruption, provided they are able to tolerate the higher toxicity burden (in particular, infections). Until longer‐term data from ongoing trials are available, continuous treatment with BTK inhibitors may be the preferred option in patients with TP53 disruption, with careful consideration of underlying cardiac comorbidities. The phosphoinositide 3‐kinase (PI3K) inhibitor idelalisib in combination with rituximab, or continuous treatment with venetoclax monotherapy, remain approved options in patients with TP53 disruption, if BTK inhibitors are unsuitable or unavailable. Recommendation Continuous treatment is suggested over time‐limited treatment, unless time‐limited treatment is preferred by shared decision‐making Relevant for:All patients with TP53 disruptionLevel of EvidenceIGrade of RecommendationAJohn Wiley & Sons, Ltd. Recommendation Continuous treatment is suggested over time‐limited treatment, unless time‐limited treatment is preferred by shared decision‐making Relevant for:All patients with TP53 disruptionLevel of EvidenceIGrade of RecommendationAJohn Wiley & Sons, Ltd. Recommendation Triplet therapies may add additional benefit with respect to longer treatment‐free intervals in vs doublet combinations Relevant for:Patients with TP53 disruption who may tolerate the higher risk of infections associated with triplet therapyLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation Triplet therapies may add additional benefit with respect to longer treatment‐free intervals in vs doublet combinations Relevant for:Patients with TP53 disruption who may tolerate the higher risk of infections associated with triplet therapyLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. TREATMENT OF RELAPSED/REFRACTORY DISEASE Despite the significant advances in targeted therapy, a substantial proportion of patients with CLL will relapse and require subsequent lines of therapy. Relapse is commonly recognized by increasing lymphocytosis, (re‐)occurrence of cytopenias, or lymphadenopathy. However, treatment should only be initiated in patients with cytopenias, bulky lymphadenopathy, or symptomatic disease, fulfilling iwCLL criteria for treatment. The choice of treatment in R/R CLL depends on the type of prior therapy (time‐limited treatment vs. continuous), duration of response, reason for treatment discontinuation (progression vs. intolerance), presence of adverse biological features including TP53 aberrations, and IGHV status. Additionally, patient age, comorbidities, patient preferences, drug access, and ease of administration may influence therapeutic decisions as described in Section 6 of this publication (First‐line treatment for CLL). For all patients with R/R disease, particularly those with poor risk features or after multiple prior therapies, participation in a clinical trial should be actively considered whenever available. Clinical trials provide access to innovative and potentially more effective treatments under closely monitored conditions without increasing risk (compared with standard care). Relapse after CIT Patients relapsing after CIT should not be re‐treated with chemotherapy if targeted therapies are available and accessible. Randomized trials and real‐world data have shown superior efficacy of targeted agents over repeated CIT. Venetoclax + rituximab 108 or a second‐generation covalent BTK inhibitor (cBTKi) such as acalabrutinib 96 or zanubrutinib 97 is preferred (Figure 3A). (A) Treatment of patients with relapsed/refractory CLL (after continuous CIT). (B) Treatment of patients with relapsed/refractory CLL (on/after continuous Tx). (C) Treatment of patients with relapsed/refractory CLL (after venetoclax‐based treatment). CIT, chemoimmunotherapy; CLL, chronic lymphocytic leukemia. Relapse after covalent BTK inhibitor therapy Patients with disease progression following treatment with cBTKi should not be exposed to another cBTKi but switched to a venetoclax‐based regimen (Figure 3B) 109 , 110 or to the ncBTKi pirtobrutinib (approved in this setting). Patients stopping cBTKi due to adverse events and then relapsing after a period of observation may be treated again with the same or another cBTKi or ncBTKi 111 , 112 , 113 Studies have reported overall response rates (ORRs) of 70%–80% for venetoclax after cBTKi failure, with improved outcomes versus idelalisib or CIT. 114 Venetoclax + rituximab offers the advantage of time‐limited treatment, and is often preferred for patients with comorbidities or intolerance to cBTKi 115 Pirtobrutinib has shown a 69% response rate and a median PFS of 14 months in patients pretreated with cBTKi (50% of those patients were double‐exposed, i.e., pretreated also with venetoclax). 111 , 116 Efficacy is higher in patients with earlier relapse, and cardiac adverse events appear to be lower versus ibrutinib in a head‐to‐head comparison. 103 Relapse after time‐limited treatment venetoclax Re‐treatment with a venetoclax‐based regimen, especially venetoclax + rituximab, is feasible in selected patients who have had a durable prior response. 91 , 108 , 114 , 115 Re‐treatment is more effective when the prior treatment‐free interval exceeds 2 years, whereas early relapse warrants switching drug class (Figure 3C). 108 , 117 In both clinical trials and in real‐world settings, ORRs of 72%–80% have been reported, with median PFS of approximately 23–25 months. 108 , 114 Venetoclax + obinutuzumab is not approved in relapsed disease, but obinutuzumab has shown superiority over rituximab when used in combination with venetoclax as a first‐line treatment. 87 Venetoclax + ibrutinib or other combinations of BCL‐2 inhibitors + BTK inhibitors in the R/R setting are also not approved, but initial data appear promising. 93 Alternatively, cBTKi therapy is appropriate in the relapse setting after time‐limited treatment venetoclax if not previously used otherwise ncBTKi becomes the preferred option. 89 , 118 Double‐exposed and double‐refractory disease “Double‐exposed” refers to patients who have received both BTK and BCL‐2 inhibitors, but have discontinued either as planned or for adverse events. In this subgroup of patients, discontinuation is not due to progression, and patients can be re‐exposed to either class of drugs as a combination of the two drug classes is off‐label in this setting. 119 , 120 “Double‐refractory” refers to patients who have disease progression following treatment with both classes (after continuous cBTKi and after continuous venetoclax or early after time‐limited treatment venetoclax‐based therapy), and represents a high‐risk group for which the ncBTKi pirtobrutinib is the preferred treatment option 121 ; in cases where access is not possible, idelalisib + rituximab can also be used. 122 , 123 “Double‐exposed with single refractoriness” refers to patients who have received both BTK and BCL‐2 inhibitors, but having disease progression following treatment only to one the classes. These patients can be re‐exposed to the class they are not refractory to or may switch to ncBTKi pirtobrutinib. Allogeneic stem cell transplantation (alloSCT) should be considered for patients who are double‐refractory, using pirtobrutinib or idelalisib + rituximab as a bridge to transplant in eligible patients with controlled disease with aim of achieving maximal response before transplantation. AlloSCT can provide long‐term remission in about 50% of eligible patients with disease control prior to transplant, though data in the double‐refractory setting are scant. 124 , 125 , 126 Consideration for inclusion in clinical trials of novel agents (such has BTK degraders, 127 bispecific antibodies, 128 chimeric antigen receptor [CAR] T‐cell therapy 129 ) is strongly recommended in patients who are double‐refractory. Autologous T‐cell therapies including CAR T cells (e.g., lisocabtagene maraleucel [liso‐cel]) are not approved in EU, but are available in other countries. In the TRANSCEND CLL 004 study, complete response (CR) rates with CAR T‐cell therapy were ~18% lower in CLL than in other B‐cell malignancies. BTK degraders show promising results in phase 1 clinical trials, with ORRs in the range of 70% and with satisfactory safety profiles. Bispecific antibodies have yielded CR rates near 40%, although data are early and mostly in monotherapy. Recommendation Time‐limited treatment with venetoclax + CD20 antibody or continuous treatment with a second‐generation covalent BTK inhibitor are preferred treatments for most patients with R/R CLL [I, A] Relevant for:All patients with relapse/progressive disease after CITLevel of EvidenceIGrade of RecommendationAJohn Wiley & Sons, Ltd. Recommendation Time‐limited treatment with venetoclax + CD20 antibody or continuous treatment with a second‐generation covalent BTK inhibitor are preferred treatments for most patients with R/R CLL [I, A] Relevant for:All patients with relapse/progressive disease after CITLevel of EvidenceIGrade of RecommendationAJohn Wiley & Sons, Ltd. Recommendation Patients with prior intolerance to ibrutinib should be offered acalabrutinib, zanubrutinib, or a venetoclax‐based regimen. Patients with intolerance to acalabrutinib or zanubrutinib may switch to another second‐generation covalent BTK inhibitor Relevant for:All patients with intolerance to covalent BTK inhibitorsLevel of EvidenceIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation Patients with prior intolerance to ibrutinib should be offered acalabrutinib, zanubrutinib, or a venetoclax‐based regimen. Patients with intolerance to acalabrutinib or zanubrutinib may switch to another second‐generation covalent BTK inhibitor Relevant for:All patients with intolerance to covalent BTK inhibitorsLevel of EvidenceIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation Patients with disease progression on covalent BTK inhibitor therapy should switch to venetoclax‐based regimens or be treated with a non‐covalent BTK inhibitor Relevant for:All patients with disease progression on covalent BTK inhibitor therapyLevel of EvidenceIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation Patients with disease progression on covalent BTK inhibitor therapy should switch to venetoclax‐based regimens or be treated with a non‐covalent BTK inhibitor Relevant for:All patients with disease progression on covalent BTK inhibitor therapyLevel of EvidenceIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation After time‐limited treatment with venetoclax (either in combination with a BTK inhibitor or a CD20 antibody), a covalent BTK inhibitor or re‐treatment with venetoclax may be considered, depending on prior response and time since discontinuation Relevant for:All patients with relapse after prior time‐limited treatment with venetoclax‐based therapyLevel of EvidenceIVGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation After time‐limited treatment with venetoclax (either in combination with a BTK inhibitor or a CD20 antibody), a covalent BTK inhibitor or re‐treatment with venetoclax may be considered, depending on prior response and time since discontinuation Relevant for:All patients with relapse after prior time‐limited treatment with venetoclax‐based therapyLevel of EvidenceIVGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation Patients with double‐refractory CLL should receive the non‐covalent BTK inhibitor pirtobrutinib, or, if not available, idelalisib + rituximab; these agents should also be considered as a bridge to alloSCT in eligible patients Participation in clinical trials, if accessible, is highly recommended Relevant for:Double‐refractory disease (i.e., venetoclax‐resistant disease with progression on covalent BTK inhibitor therapy)Level of EvidenceII/IIIGrade of RecommendationAJohn Wiley & Sons, Ltd. Recommendation Patients with double‐refractory CLL should receive the non‐covalent BTK inhibitor pirtobrutinib, or, if not available, idelalisib + rituximab; these agents should also be considered as a bridge to alloSCT in eligible patients Participation in clinical trials, if accessible, is highly recommended Relevant for:Double‐refractory disease (i.e., venetoclax‐resistant disease with progression on covalent BTK inhibitor therapy)Level of EvidenceII/IIIGrade of RecommendationAJohn Wiley & Sons, Ltd. Recommendation Patients with double‐refractory CLL should avoid discontinuation of ongoing therapy until the next line of treatment is available to prevent disease flare Relevant for:Patients with disease progression on targeted treatmentLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation Patients with double‐refractory CLL should avoid discontinuation of ongoing therapy until the next line of treatment is available to prevent disease flare Relevant for:Patients with disease progression on targeted treatmentLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. MANAGEMENT OF RT RT refers to an aggressive lymphoma occurring in 2%–10% of patients with CLL. The decision algorithm is detailed in Figure 4. Decision algorithm for patients with Richter transformation. 18F‐FDG, 2‐deoxy‐2‐(18F)fluoro‐d‐glucose; allo‐HSCT, allogeneic hematopoietic stem cell transplantation; axi‐cel, axicabtagene ciloleucel; BCL‐2i, inhibitor of the B‐cell lymphoma 2 protein; BTKi, Bruton tyrosine kinase inhibitor; CAR, chimeric antigen receptor; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B‐cell lymphoma; PET, positron emission tomography; R‐CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R‐DA‐EPOCH, dose‐adjusted rituximab, etoposide prednisolone, vincristine, cyclophosphamide and doxorubicin; RR, relapsed/refractory; RT, Richter transformation; liso‐cel, lisocabtagene maraleucel. Pathological examination, ideally through excisional biopsy, is required to establish the diagnosis and exclude other entities such as accelerated CLL. 5 , 8 , 130 , 131 The most common histologic subtype is diffuse large B‐cell lymphoma (RT‐DLBCL), which requires the presence of sheets of large cells. Less frequently, RT presents as classical Hodgkin lymphoma (RT‐cHL). Pseudo‐RT should be recognized in patients discontinuing BTK inhibitors and should be promptly differentiated. 8 An elevated 18‐FDG‐PET/CT uptake correlates with RT, and can guide biopsy, although the optimal threshold is debated in the targeted therapies era. 132 The evaluation of the clonal relationship between RT and the underlying CLL by IGHV‐IGHD‐IGHJ gene sequencing is recommended for optimal management of patients. Clonally‐related RT (~80% of cases) exhibit poorer outcomes compared to clonally‐unrelated RT, 133 though there is no data from a large multivariate analysis confirming the inferior prognosis. Assessment for del(17p)/TP53 aberrations (present in 50%–60% of cases and associated with poor prognosis) is advised. 133 Patients with clonally‐unrelated RT‐DLBCL should be treated as de novo DLBCL. No standard therapy has been defined for clonally related disease, and clinical trials should be the preferred option. RT‐cHL should be treated per cHL guidelines. Accelerated CLL, which is described as CLL with an increased proliferation rate and without transformation, should be treated as CLL. When the clonal relation is not established, CIT regimens generally used for de novo DLBCL are the default options in RT‐DLBCL, but these have demonstrated limited efficacy, with CR rates ranging from 5% to 38%, with median OS rarely exceeding one year. No data from randomized studies is available. Enrolling patients in clinical trials is therefore the preferred option. Phase 2 studies have evaluated targeted therapies and immunotherapies developed for use in lymphoid malignancies. BCL‐2 or BTK inhibitors have shown limited efficacy as monotherapies. Acalabrutinib has demonstrated an ORR of 40%. 134 The subgroup analysis of the phase 1/2 BRUIN study showed that 50% of their patients with RT achieved an overall response with the ncBTK inhibitor pirtobrutinib. 135 Acalabrutinib and pirtobrutinib could be potentially used as bridging therapy prior a more intensive approach. Given the short duration of response, hematopoietic stem‐cell transplantation should be considered in eligible patients with clonally related RT‐DLBCL and satisfactory response. 136 , 137 The combination of venetoclax and R‐da‐EPOCH achieved a CR rate of 50%. 138 Immune checkpoint inhibitor combinations have yielded an ORR of 58% in the RT1 trial (zanubrutinib and tislelizumab) 139 and 68% in the MOLTO trial (obinutuzumab, atezolizumab, and venetoclax). 140 Bispecific T‐cell engagers (TCE) and CAR T‐cell therapies represent other promising approaches. The BLINART trial showed that the anti‐CD3/anti‐CD19 TCE blinatumomab induced CR in 20% of patients with no CR after two cycles of R‐CHOP. 141 In a recent evaluation, the anti‐CD3/anti‐CD20 TCE epcortimamab demonstrated an ORR of 48%. 142 In two retrospective analysis of 69 and 54 patients, respectively, receiving CD19‐directed CAR T‐cell therapy, the CR rate was 46% in both, with a median PFS of 4.7 and 8 months, respectively. 143 , 144 Recommendation DLBCL in patients with CLL should undergo evaluation of clonal relationship, because de novo DLBCL should be treated according to DLBCL guidelines Relevant for:Patients with histological proven DLBCL and concurrent/previous CLLLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation DLBCL in patients with CLL should undergo evaluation of clonal relationship, because de novo DLBCL should be treated according to DLBCL guidelines Relevant for:Patients with histological proven DLBCL and concurrent/previous CLLLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation Patients with RT‐DLBCL should be offered participation in clinical trials whenever possible Relevant for:All patients with RT‐DLBCLLevel of EvidenceIIGrade of RecommendationAJohn Wiley & Sons, Ltd. Recommendation Patients with RT‐DLBCL should be offered participation in clinical trials whenever possible Relevant for:All patients with RT‐DLBCLLevel of EvidenceIIGrade of RecommendationAJohn Wiley & Sons, Ltd. Recommendation Outside of clinical trials, CIT is the standard regimen for RT‐DLBCL Relevant for:All patients with RT‐DLBCLLevel of EvidenceIIIGrade of RecommendationCJohn Wiley & Sons, Ltd. Recommendation Outside of clinical trials, CIT is the standard regimen for RT‐DLBCL Relevant for:All patients with RT‐DLBCLLevel of EvidenceIIIGrade of RecommendationCJohn Wiley & Sons, Ltd. Recommendation Patients with clonal RT‐DLBCL in remission, and being fit enough, should be offered alloSCT for consolidation (when a suitable donor is available) Relevant for:Fit patients with RT‐DLBCLLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. Recommendation Patients with clonal RT‐DLBCL in remission, and being fit enough, should be offered alloSCT for consolidation (when a suitable donor is available) Relevant for:Fit patients with RT‐DLBCLLevel of EvidenceIIIGrade of RecommendationBJohn Wiley & Sons, Ltd. AUTHOR CONTRIBUTIONS Barbara Eichhorst and Paolo Ghia: Conceptualization; writing—original draft; writing—review and editing; supervision. Francesc Bosch: Writing—original draft; writing—review and editing. Ruth Clifford: Writing—original draft; writing—review and editing. Michael Gregor: Writing—original draft; writing—review and editing. Romain Guieze: Writing—original draft; writing—review and editing. Arnon P. Kater: Writing—original draft; writing—review and editing. Carsten U. Niemann: Writing—original draft; writing—review and editing. Sarka Pospisilova: Writing—original draft; writing—review and editing. Tadeusz Robak: Writing—original draft; writing—review and editing. Anna Schuh: Writing—original draft; writing—review and editing. Kostas Stamatopoulos: Writing—original draft; writing—review and editing. Tamar Tadmor: writing—original draft; writing—review and editing. Nick York: Writing—original draft; writing—review and editing. CONFLICT OF INTEREST STATEMENT BE: Received research grants from Abbvie, AstraZenca, BeOne, Janssen and Roche; in addition she served as consulted or speaker for Abbvie, AstraZenca, BeOne, Galapagos, Lilly, MSD and Roche. PG: Advisory board/consultant: AbbVie, AstraZeneca, BeOne, BMS, Johnson & Johnson, Lilly, MSD, Nurix, Roche. Research funding: AbbVie, AstraZeneca, BeOne, BMS, Johnson & Johnson, Lilly, MSD FB: Received research grants, speaker honoraria/consulting: Abbvie, Allogene, Amgen, Autolus, AstraZeneca, BeOne, BMS, Gilead (Kite), Johnson&Johnson, Lilly, MSD, Novartis, Roche, Takeda, TG threapeutics RC: No conflict of interest. MG: Advisory board participation/consulting: AbbVie, Amgen, AstraZeneca, BeOne, BMS, Daichi/Sankyo, GSK, Johnson & Johnson, Lilly, Sanofi, Servier (all fees paid to the institution). Travel grant: AbbVie, BeOne, Johnson & Johnson, Pfizer, Servier. RG: Speaker Honoraria: Johnson and Johnson, Abbvie, BeOne Medicines, Astrazeneca, Lilly; Advisory Board Participation: Johnson and Johnson, Abbvie, BeOne Medicines, Astrazeneca, Lilly, Ascentage Pharma; Consultancy Roles: Johnson and Johnson, Abbvie, BeOne Medicines, Astrazeneca, Lilly; Research Funding: Johnson and Johnson, Abbvie, BeOne Medicines, Astrazeneca, Lilly. APK: has received research grants from Johnson & Johnson, AbbVie, Roche/Genentech, Bristol Myers Squibb, AstraZeneca, and Genmab, and honoraria (paid to the institution) from BeiGene, Johnson & Johnson, AstraZeneca, AbbVie, and Genmab. CUN: has received research funding and/or consultancy fees from Abbvie, AstraZeneca, Janssen, Beigene, Genmab, Octapharma, Takeda, MSD, Lilly, CSL Behring, Galapagos, Synamics, Novo Nordisk Foundation. SP: No conflict of interest. TR: Speaker Honoraria: AstraZeneca, BeOne Medicines; Advisory Board Participation: AstraZeneca, BeOne Medicines, Lilly and Johnson & Johnson; Consultancy Roles: AstraZeneca, Eli Lilly; Research Funding: AbbVie, Acerta Pharma, AstraZeneca, BeOne Medicines, Gilead Sciences, GSK, Johnson & Johnson, Eli Lilly, Merck; Institutional Support: None; Travel grants: AstraZeneca, BeOne Medicines; Johnson & Johnson, AS: Received research grants from AstraZeneca and Johnson & Johnson. Served as consultant or speaker for Abbvie, AstraZeneca, BeOne, and Lilly. KS: Honoraria: AbbVie, AstraZeneca, BeOne Medicines, Johnson&Johnson, Lilly. Advisory Board participation: AbbVie, AstraZeneca, BeOne Medicines, Johnson&Johnson. Research funding: AbbVie, AstraZeneca, BeOne Medicines, Johnson&Johnson. TT: Advisory Board Participation: Johnson and Johnson, Abbvie, BeOne Medicines, Astrazeneca, Lilly, Roche. Research Funding: Johnson and Johnson, Abbvie, BeOne Medicines, Roche. NY: Advisory board participation, consultation & honoraria: AstraZeneca, Johnson and Johnson, Takeda. FUNDING This research received no funding.